Close Menu
PNN DigitalPNN Digital
    Facebook X (Twitter) Instagram
    PNN DigitalPNN Digital
    • Business
    • National
    • Entertainment
    • Lifestyle
    • Education
    • Press Release
    • Submit Your PR
    PNN DigitalPNN Digital
    Home - Business - Thyrocare Reports Strong Q1FY26 Results with 23% YoY Revenue Growth
    Business

    Thyrocare Reports Strong Q1FY26 Results with 23% YoY Revenue Growth

    PNN Online DeskBy PNN Online DeskJuly 31, 2025No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Thyrocare
    Share
    Facebook Twitter LinkedIn Pinterest Email

    New Delhi [India], July 31:  Thyrocare Technologies Limited (hereinafter referred to as “THYROCARE” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, has announced its financial results for the first quarter of FY26, ending June 30, 2025. The company reported a consolidated revenue of ₹193.03 crore for Q1FY26, marking a solid 23 percent growth compared to ₹156.91 crore in the same quarter last year.

    This growth was largely driven by the company’s core Pathology segment, which posted a 25 percent year-on-year increase. Within this vertical, franchise revenue increased by 20 percent, while partnership revenue saw a sharper growth of 36 percent. The Radiology segment also contributed to the topline, registering a 6 percent year-on-year increase. Total test volume for the quarter reached 46.9 million, representing a 15 percent rise over Q1FY25.

    Thyrocare maintained strong profitability during the quarter. Gross margin stood at ₹137.40 crore, growing 23 per cent year-on-year and maintaining a margin of 71 per cent, consistent with the previous year. Normalised EBITDA before ESOP expenses reached ₹63.35 crore, reflecting 42 per cent growth over ₹44.73 crore in Q1 FY25. Reported EBITDA came in at ₹57.46 crore, up 37 per cent from ₹42.01 crore a year earlier. The normalised EBITDA margin improved from 29 per cent to 33 per cent, while the reported EBITDA margin rose from 27 per cent to 30 per cent.

    Profit after tax, including exceptional items, was recorded at ₹38.06 crore, a significant 62 per cent jump from ₹23.47 crore in the same quarter last year. The PAT margin also improved considerably, moving from 15 per cent in Q1FY25 to 20 per cent in Q1FY26. These numbers reflect the company’s enhanced operational efficiency and strong execution across its diagnostic network.

    The company also expanded its physical footprint during the quarter by launching new diagnostic laboratories in Bhagalpur, Kashmir, and Roorkee. These new labs are expected to further strengthen Thyrocare’s presence in underserved regions and support the increasing test volumes from both franchise and partner-driven locations.

    In addition to the strong quarterly performance, Thyrocare’s full-year financials for FY25 provide a stable reference point. The company had reported revenue of ₹687.32 crore, gross margin of ₹496.25 crore at 72 per cent, normalised EBITDA of ₹209.94 crore at 31 per cent, and reported EBITDA of ₹189.21 crore at 28 per cent. PAT for the year stood at ₹90.02 crore, with a 13 percent margin. The improvements seen in Q1FY26 indicate a strong start to the financial year and build momentum for sustained performance going forward.

    Speaking on the results, the company’s management reaffirmed its commitment to leveraging technology, scalability, and partner-led growth to provide affordable and accessible diagnostic services across India. Thyrocare continues to prioritise operational efficiency while exploring new regions and enhancing the quality and reach of its test offerings.

    Thyrocare Technologies Limited remains a pioneer in the Indian diagnostics space, with a strong emphasis on automation, network expansion, and high-volume testing. The company’s approach combines low-cost operations with a high-quality service framework, positioning it for sustainable growth in both the pathology and radiology segments.

    If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

    23% YoY Revenue Growth Q1FY26 Results Thyrocare
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    PNN Online Desk
    • Website

    Related Posts

    Moving Made Easy: VshiftU Brings Trusted Packers & Movers Under One Roof

    August 1, 2025

    Apollo Hospitals, Jubilee Hills Performs Youngest Valve-in-Valve TAVI in India

    August 1, 2025

    Shining victory of Blackk & One Badminton Academy Players in Gujarat State Badminton Championship 2025

    August 1, 2025
    Add A Comment

    Comments are closed.

    Recent Posts
    • Moving Made Easy: VshiftU Brings Trusted Packers & Movers Under One Roof
    • Apollo Hospitals, Jubilee Hills Performs Youngest Valve-in-Valve TAVI in India
    • Shining victory of Blackk & One Badminton Academy Players in Gujarat State Badminton Championship 2025
    • Health and Wellness Entrepreneur Sak Narwal Talks Oral Peptides – A Simpler Path to Metabolic Wellness
    • Sid Sriram Announces His First-Ever India Tour in 2025 – A Landmark Musical Homecoming Across Bengaluru, Chennai, and Hyderabad

    Moving Made Easy: VshiftU Brings Trusted Packers & Movers Under One Roof

    August 1, 2025

    Apollo Hospitals, Jubilee Hills Performs Youngest Valve-in-Valve TAVI in India

    August 1, 2025

    Shining victory of Blackk & One Badminton Academy Players in Gujarat State Badminton Championship 2025

    August 1, 2025

    Health and Wellness Entrepreneur Sak Narwal Talks Oral Peptides – A Simpler Path to Metabolic Wellness

    August 1, 2025

    Sid Sriram Announces His First-Ever India Tour in 2025 – A Landmark Musical Homecoming Across Bengaluru, Chennai, and Hyderabad

    August 1, 2025

    Nyra Banerjee Shines as Celebrity Guest at Miss & Mrs India Dazzling Divas season 1 , 2025 & Business Iconic Awards Night season 1 , 2025

    July 31, 2025
    PNN Digital
    2025 © pnn.digital

    Type above and press Enter to search. Press Esc to cancel.